Complications of intravitreal anti-angiogenic therapy Intravitreal injections are typically well tolerated. Minor complications such as subconjunctival hemorrhage and local irritation are common. In rare instances, serious ocular complications can occur, including inflammation, persistent ocular hypertension, retinal detachment, vitreous hemorrhage, and endophthalmitis. The rate of endophthalmitis is approximately 1 in 2000 or lower (see also Chapter 20 of this volume). Systemic administration of bevacizumab for cancer treatment has been shown to increase the risk of hypertension; thromboembolic events, especially myocardial infarctions and cerebral vascular accidents; gastrointestinal perforations; and bleeding. There is conflicting evidence whether intravitreal injections of any of these agents increase the rate of these complications.